Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-κB/COX-2 pathway

Theranostics

Volumn 5, Issue 3, 2015, Pages 302-321

  Liao, Kun ^b   Xia, Bin ^b   Zhuang, Qun Ying ^a   Hou, Meng Jun ^b   Zhang, Yu Jing ^b   Luo, Bing ^a   Qiu, Yang ^a   Gao, Yan Fang ^b   Li, Xiao Jie ^b   Chen, Hui Feng ^b   Ling, Wen Hua ^b   He, Cheng Yong ^a   Huang, Yi Jun ^c   Lin, Yu Chun ^a,b   Lin, Zhong Ning ^a,b  

^a XIAMEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAY 10404; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PARTHENOLIDE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; SESQUITERPENE;

ARTICLE; CANCER STEM CELL; CELL DEATH; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; GENE EXPRESSION PROFILING; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASTIC STEM CELLS; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 84924370673     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8387     Document Type: Article

References (50)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005; 365: 2041-54. doi:10.1016/S0140-6736(05)66698-6.
2. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003; 39: 2121-35. doi:10.1016/S0959-8049(03)00367-8.
3. Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, et al. Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2011; 128: 79-85. doi:10.1016/j.anorl.2010.10.003.
4. Wilson BJ, Schatton T, Frank MH, Frank NY. Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. Curr Colorectal Cancer Rep. 2011; 7: 128-35. doi:10.1007/s11888-011-0093-2.
5. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013; 27: 13-24. doi:Doi 10.1096/Fj.12-218222.
6. Kakarala M, Wicha MS. Cancer stem cells: implications for cancer treatment and prevention. Cancer J. 2007; 13: 271-5. doi:10.1097/PPO.0b013e318156da4e.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-11. doi:10.1038/35102167.
8. Mannelli G, Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev. 2012; 38: 515-39. doi:DOI 10.1016/j.ctrv.2011.11.007.
9. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001; 7: 1028-34. doi:10.1038/nm0901-1028.
10. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007; 67: 3716-24. doi:10.1158/0008-5472.can-06-4343.
11. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett. 2008; 268: 1-9. doi:10.1016/j.canlet.2008.03.048.
12. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007; 67: 4827-33. doi:10.1158/0008-5472.CAN-06-3557.
13. Knight DW. Feverfew: chemistry and biological activity. Nat Prod Rep. 1995; 12: 271-6. doi: 10.1039/NP9951200271.
14. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM. Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis. 2004; 25: 2191-9. doi:10.1093/carcin/bgh234.
15. Lesiak K, Koprowska K, Zalesna I, Nejc D, Duchler M, Czyz M. Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro. Melanoma Res. 2010; 20: 21-34. doi:10.1097/CMR.0b013e328333bbe4.
16. Zuch D, Giang AH, Shapovalov Y, Schwarz E, Rosier R, O'Keefe R, et al. Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem. 2012; 113: 1282-91. doi:10.1002/jcb.24002.
17. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005; 105: 4163-9. doi:10.1182/blood-2004-10-4135.
18. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007; 110: 4427-35. doi:10.1182/blood-2007-05-090621.
19. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 2008; 9: R83. doi:10.1186/gb-2008-9-5-r83.
20. Ghantous A, Sinjab A, Herceg Z, Darwiche N. Parthenolide: from plant shoots to cancer roots. Drug Discov Today. 2013; 18: 894-905. doi:10.1016/j.drudis.2013.05.005.
21. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat. 2008; 111: 419-27. doi:10.1007/s10549-007-9798-y.
22. Czyz M, Koprowska K, Sztiller-Sikorska M. Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol Ther. 2013; 14: 135-45. doi:10.4161/cbt.22952.
23. Curry EA 3rd, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs. 2004; 22: 299-305. doi:10.1023/B:DRUG.0000026256.38560.be.
24. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988; 2: 189-92. doi:10.1016/S0140-6736(88)92289-1.
25. Ghosh S, Hayden MS. Celebrating 25 years of NF-kappaB research. Immunol Rev. 2012; 246: 5-13. doi:10.1111/j.1600-065X.2012.01111.x.
26. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441: 431-6. doi:10.1038/nature04870.
27. Sun W, Guo MM, Han P, Lin JZ, Liang FY, Tan GM, et al. Id-1 and the p65 subunit of NF-kappaB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis. 2012; 33: 810-7. doi:10.1093/carcin/bgs027.
28. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001; 98: 2301-7. doi:10.1182/blood. V98.8.2301.
29. Zhou J, Zhang Y. Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle. 2008; 7: 1360-70. doi:10.4161/cc.7.10.5953.
30. Salati S, Risueno RM, Bhatia M. Targeting LSCs: powering an old tool. Blood. 2008; 111: 5423-4. doi:10.1182/blood-2008-03-144063.
31. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000; 69: 145-82. doi:10.1146/annurev.biochem.69.1.145.
32. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999; 18: 7908-16. doi:10.1038/sj.onc.1203286.
33. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009; 30: 377-86. doi:10.1093/carcin/bgp014.
34. Ma HI, Chiou SH, Hueng DY, Tai LK, Huang PI, Kao CL, et al. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation. J Neurosurg. 2011; 114: 651-62. doi:10.3171/2009.11.JNS091396.
35. Muraki C, Ohga N, Hida Y, Nishihara H, Kato Y, Tsuchiya K, et al. Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells. Int J Cancer. 2012; 130: 59-70. doi:Doi 10.1002/Ijc.25976.
36. Pang LY, Gatenby EL, Kamida A, Whitelaw BA, Hupp TR, Argyle DJ. Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation. PLoS One. 2014; 9: e83144. doi:10.1371/journal.pone.0083144.
37. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods. 2006; 3: 715-9. doi:10.1038/nmeth924.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25: 402-8. doi:10.1006/meth.2001.1262.
39. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A. 1994; 91: 3228-32. doi:10.1073/pnas.91.8.3228.
40. Habeeb AG, Praveen Rao PN, Knaus EE. Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem. 2001; 44: 2921-7. doi: 10.1021/jm0101287.
41. Zhang S, Won YK, Ong CN, Shen HM. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents. 2005; 5: 239-49. doi:10.2174/1568011053765976.
42. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013; 2: 3. doi:10.1186/2001-1326-2-3.
43. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008; 27: 1749-58. doi:10.1038/sj.onc.1210811.
44. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol. 2002; 20: 973-81. doi: 10.1200/JCO.20.4.973.
45. Østergaard, Ernst A, Labouriau R, Dagilien' E, Krarup HB, Christensen M, et al. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand J Gastroenterol. 2009; 44: 65-73. doi:10.1080/00365520802400826.
46. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des. 2004; 10: 647-57. doi:10.2174/1381612043453117.
47. Kang JH, Song KH, Jeong KC, Kim S, Choi C, Lee CH, et al. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer. 2011; 11: 334. doi:10.1186/1471-2407-11-334.
48. Soares MP, Muniappan A, Kaczmarek E, Koziak K, Wrighton CJ, Steinhauslin F, et al. Adenovirus-mediated expression of a dominant negative mutant of p65/RelA inhibits proinflammatory gene expression in endothelial cells without sensitizing to apoptosis. J Immunol. 1998; 161: 4572-82.
49. Annabi B, Laflamme C, Sina A, Lachambre MP, Beliveau R. A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells. J Neuroinflammation. 2009; 6: 8. doi:10.1186/1742-2094-6-8.
50. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A. 2001; 98: 6905-10. doi:10.1073/pnas.121016998.